期刊文献+

贝那普利联合缬沙坦治疗高血压伴蛋白尿的临床研究 被引量:4

A Clinical Research of the Treatment in Hypertension with Proteinuria by Using Benazepril Lotensin and Valsartan
下载PDF
导出
摘要 目的:观察贝那普利联合缬沙坦治疗高血压伴蛋白尿的疗效。方法:将164例高血压伴蛋白尿患者随机分为治疗组和对照组,治疗组给予贝那普利联合缬沙坦治疗,对照组给予贝那普利治疗。结果:治疗组24h尿蛋白及Scr较对照组均明显改善(P<0.05)。结论:贝那普利联合缬沙坦治疗高血压伴蛋白尿较单用贝那普利治疗效果明显。 Objective:To observe the curative effect for hypertension with proteinuria by using benazepril lotensin and valsatan.Methods:164 cases of hypertension with proteinuria were randomly divided into treatment group and control group.Treatment group was given benazepril lotensin and valsatan,while controlled group was given benazepril lotensin.Results:Compared with controlled group Proteinuria and Scr of treatment group were obviously improved(P0.05)in twenty four hours.Conclusion:It indicates that the effect of the treatment group given benazepril lotensin and valsartan is better than the control group only given benazepril lotensin
出处 《医学理论与实践》 2011年第7期752-753,共2页 The Journal of Medical Theory and Practice
关键词 贝那普利 缬沙坦 高血压伴蛋白尿 Benazepril lotensin Valsartan Hypertension with proteinuria
  • 相关文献

参考文献3

二级参考文献12

  • 1刘力生.2004年中国高血压防治指南(实用本)[J].中华心血管病杂志,2004,32(12):1060-1064. 被引量:2620
  • 2Matsuzaki G, Ishizaka N, Furuta K, et al. Comparison of vasculoprotective effects of benidipine and losartan in a rat model of metabolic syndrome. Eur J Pharmacol, 2008,587:237-242.
  • 3Takayama M, Arakawa E, Yao K, et al. Effects of combination of angiotensin receptor blocker and calcium channel blocker on oxLDL levels and cardiovascular dysfunction in Dahl rats. Pharmacology, 2006,77 : 179-187.
  • 4Shikata C, Sekikawa T, Kimura N, et al. Beneficial effect of combination therapy with antihypertensive drugs in patients with hyprtension. Exp Clin Cardiol, 2007,12:33-36.
  • 5Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE) : a position paper of the National Kidney Foundation. Am J Kidney Dis, 1999,33 : 1004-1010.
  • 6Uzu T, Nishimura M, Fujii T, et al. Benidipine attenuates glomerular hypertension and reduces albuminuria in patients with metabolic syndrome. Hypertens Res, 2007,30 : 161-165.
  • 7Akizuki O, Inayoshi A, Kitayama T, et al. Blockade of T-type voltage-dependent Ca2 + channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R. Eur J Pharmacol, 2008, 584: 424-434.
  • 8Saito F, Fujita H, Takahashi A, et al. Renoprotective effect and cost-effectiveness of using benidipine, a calcium channel blocker, to lower the dose of angiotensin receptor blocker in hypertensive patients with albuminuria. Hypertens Res, 2007, 30:39-47.
  • 9Hayashi K, Wakino S, Homma K, et al. Pathophysiological significance of T-type Ca2 + channels: role of T-type Ca2 + channels in renal microcirculation. J Pharmacol Sci, 2005, 99 : 221-227.
  • 10Gashti CN,Bakris GL. The role of calcium antagonists in chronic kidney disease. Curr Opin Nephrol Hypertens, 2004, 13: 155- 161.

共引文献22

同被引文献22

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部